Peptide sprays surge as needle-free alternatives to injections gain traction

The peptide market is expanding rapidly, with global sales reaching $140.86 billion in 2025. By 2033, this figure is expected to more than double to $294.58 billion. One of the latest trends in this growth is the rise of peptide sprays, offering a needle-free alternative to traditional injections. Drift, a leading brand in this emerging category, has developed three science-backed peptide formulas in a simple spray format. Their products include CJC-1295 No DAC + Ipamorelin for muscle recovery, NAD for cellular energy and longevity, and GHK-CU for skin and beauty benefits. Each formula comes in a portable 30-day supply bottle, priced between $149 and $179.

The shift toward sprays aligns with research showing that nasal delivery of peptides is non-invasive, fast-acting, and capable of bypassing the blood-brain barrier. John Bains, Drift’s CEO, has openly criticised injections for their stress, pain, and inconvenience. His preference for a simpler method reflects a broader demand for user-friendly peptide solutions. Pricing for Drift’s products varies by formula. GHK-CU costs $149, while both NAD and CJC-1295 No DAC + Ipamorelin are priced at $179 each. The brand’s focus on accessibility and targeted benefits has positioned it at the forefront of this fast-growing market segment.

As peptide sprays gain popularity, brands like Drift are making the technology more accessible. Their products eliminate the need for injections while offering specific health and beauty benefits. With the global peptide market set to expand significantly, nasal delivery methods could become a standard choice for consumers.